Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis
- Veronika Dill
- , Johanna Kauschinger
- , Richard T. Hauch
- , Lars Buschhorn
- , Timo O. Odinius
- , Catharina Müller-Thomas
- , Ritu Mishra
- , Michele C. Kyncl
- , Burkhard Schmidt
- , Peter M. Prodinger
- , Dirk Hempel
- , Frauke Bellos
- , Alexander Höllein
- , Wolfgang Kern
- , Torsten Haferlach
- , Julia Slotta-Huspenina
- , Florian Bassermann
- , Christian Peschel
- , Katharina S. Götze
- , Irene C. Waizenegger
- Technical University of Munich
- Gemeinschaftspraxis Hämato-Onkologie Pasing
- Onkologiezentrum Donauwörth
- Munich Leukemia Laboratory (MLL)
- German Cancer Research Center
- Boehringer Ingelheim RCV GmbH Co KG
Research output: Contribution to journal › Article › peer-review
5
Scopus
citations